Robert Z. Orlowski: Myeloma Paper of the Day

Robert Z. Orlowski, Director of Myeloma Section at MD Anderson Cancer Center, posted on X/Twitter:

“Myeloma Paper of the Day: Matching-adjusted indirect comparison of efficacy of elranatamab versus teclistamab in patients with triple-class exposed/refractory multiple myeloma suggests that elranatamab may have better ORR and CR rates, and better PFS and OS.”

View additional information.
Source: Robert Z. Orlowski/X